FDA Investigator Kathleen M Jordan
Kathleen M Jordan has conducted inspections on 11 sites in 1 countries as of 21 Sep 2023. See below for a list of the FDA enforcement documents resulting from those inspections.
Investigator Details
Number of Inspected Sites:
11
Last Inspection Date:
21 Sep 2023
Investigator Role:
FDA Investigator
Redica ID:
Countries of Inspections:
United States of America
FDA Investigators that have inspected at least one site in common with Kathleen M Jordan:
Aditi S Thakur,
Alberto A Viciedo,
Alice S Tsao,
Alison N Stieg,
Amy N Chen,
Anne Marie Russell,
Annet R Rajan,
Anthony F Lorenzo,
Anthony W Lee,
Barbara A Gullick,
Bijoy Panicker,
Brooke K Higgins,
Brooke K Seeman,
Carol L Rehkopf,
Carole L Jones,
Chaltu Nwakijra,
Charles Yuanchia Kuo, PhD,
Chiang Syin, PhD,
Christina K Theodorou,
Clarice J Ahn,
Collins,
Cynthia A Harris, MD, RN,
David A Oluwo,
David P Rice, Jr,
Dawn L Wydner,
Derek S Smith, PhD,
Deyaa Shaheen,
Diane T Bargo,
Diane T O'brien,
Donald C Obenhuber, PhD,
Douglas A Campbell,
Dr. Dominick Roselle,
Dr. Roslyn F Powers,
Dr. Yubing Tang,
Dr. Zhihao Qiu (Peter), PhD,
Edmund F Mrak, Jr,
Edward P Potter,
Emest F Bizjak,
Ephrem Hunde, PhD,
Eric L Dong, BS,
Eric Rothschild,
Esaw,
George Pyramides,
Gerald B Seaborn, Jr,
Graeme E Price,
Graeme Price,
Guerlain Ulysse,
Hector Jcolon Torres,
Hongna Wang,
Jaison J Eapen,
James M Mason,
James M Simpson,
James W Leonette,
Jamie D Richardson,
Jamie D Swann,
Janet A Rajan,
Jazmine N Brown,
Jessica Hankins, PhD,
Jessica K Yoon,
John Dan,
John M Gusto,
Jonah S Ufferfilge,
Jonathan W Chapman,
Jose Ohernandez Guzman,
Joseph W Matthews,
Julie M Anbarchian,
Junho Pak,
Karen A Spencer,
Kelly L Anderson,
Kenneth M Gordon,
Kenneth Nieves,
Ko U Min,
Kristina L Conroy,
Lauren N Barber,
Laurissa S Flowers,
Lawrence Harmon, Jr,
LCDR Debra Emerson,
Leiyun Boone, PhD,
Lori S Lawless,
Malgorzata G Norton, PhD,
Marc S Neubauer,
Marcellinus D Dordunoo,
Marcus A Ray,
Margaret M Doherty,
Marion Michaelis,
Marlene G Swider,
Matthew M Henciak,
Megan A Haggerty,
Melissa J Garcia,
Merideth K Rose,
Michael J Vardon,
Michael R Klapal,
Michael Shanks, MS,
Mindy M Chou,
Mohamad A Chahine,
Monica Commerford, PhD,
Nadeem I Chaudhry,
Nailing Zhang,
Nebil A Oumer,
Nicholas A Violand,
Nicole K Trudel,
Nina D Patel,
Nirjal Bhattarai,
Patricia F Hughes, PhD,
Paul L Bellamy,
Pelekakis,
Prabhu P Raju,
Pratik S Upadhyay, DDC,
Qin Xu,
Quyen T Tran,
Rachael O Oyewole,
Rachel C Harrington,
Rebecca Rodriguez,
Regina Gibson Melton,
Robert H Wittorf,
Robert J Martin,
Russell J Glapion,
Saleem A Akhtar,
Samina S Khan,
Samuel Mindaye,
Sean R Marcsisin,
Sena G Dissmeyer,
Sharon K Thoma, PharmD,
Shirshendu K Deb, PhD,
Simone E Pitts,
Steven P Donald,
Tajah L Blackburn,
Tamara N Champion,
Tamil Arasu, PhD,
Thomas E Friel,
Thuy T Nguyen, LCDR,
Tonia F Bernard,
Toyin B Oladimeji,
Viviana Matta,
Viviana R Ramirez,
Vivin George,
Walter L Fava,
Wanda Y Honeyblue,
Wayne E Seifert,
William A Warnick,
William D Murray,
William H Linkroum,
Yan Wang,
Yvesna C Blaise,
Yvins Dezan,
Zakaria I Ganiyu,
Zhongren Wu
Kathleen M Jordan's Documents
Publish Date | Document Type | Title |
---|---|---|
February, 2020 | FDA 483 | Nutravail LLC - Form 483, 2020-02-06 |
September, 2021 | FDA 483 | Pharmaceutics International, Inc. - Form 483, 2021-09-29 |
April, 2021 | EIR | Cangene BioPharma, LLC - EIR, 2021-04-16 |
September, 2021 | EIR | Pharmaceutics International, Inc. - EIR, 2021-09-29 |
September, 2021 | EIR | Pharmaceutics International, Inc. - EIR, 2021-09-29 |
August, 2022 | FDA 483 | ImClone Systems LLC - Form 483, 2022-08-25 |
September, 2021 | FDA 483 | Pharmaceutics International, Inc. - Form 483, 2021-09-29 |
January, 2020 | FDA 483 | Bristol-Myers Squibb Company - Form 483, 2020-01-10 |
December, 2021 | FDA 483 | Valgene Incorporated dba Cape Drugs - Form 483, 2021-12-02 |
April, 2021 | FDA 483 | Cangene BioPharma, LLC - Form 483, 2021-04-16 |
January, 2023 | FDA 483 | Modavar Pharmaceuticals, LLC - Form 483, 2023-01-27 |
September, 2021 | FDA 483 Response | Pharmaceutics International, Inc. - Form 483R, 2021-11-18 |
April, 2021 | FDA 483 Response | Cangene BioPharma, LLC - Form 483R, 2021-05-07 |
Experience Redica Systems’ NEW investigator profiles and dashboards
Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:
- Total inspections conducted
- 483 rate
- OAI rate
- Warning Letter rate
- Inspections by Industry, Scope, and Inspection Reason
- And much more
Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.
![FDA Investigator Profile Icon](https://redica.com/document-store/images/InspectorProfile.png)
Talk to sales to access our investigator profiles
Loading...
Investigator Profiles Are Just the Tip of the Iceberg
Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:
Inspection Intelligence
- Pre-Approval Inspection (PAI) trends
- The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
- Latest 483s: see what the trends are across all FDA Investigators
- CFR Heatmap: Citations aggregated by Subpart by Year
Vendor Intelligence
- Full inspection histories for your vendors down to the specific site level
- All of the functionality mentioned above but isolated to just your vendors
Regulatory Intelligence
- Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
- All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more